AAVantgarde Bio Unveils LUCE-1 Clinical Trial Design for Usher Syndrome type 1B Gene Therapy

AAVantgarde Bio Unveils Innovative LUCE-1 Clinical Trial Design (for USH1B) at Gene Therapy Summit

Seattle, May 3, 2024 — AAVantgarde Bio, an Italian-based biotechnology company, announced the design of its LUCE-1 clinical trial for Usher Syndrome Type 1B (USH1B) at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit. Presented by Principal Investigator Prof. Francesca Simonelli, the first-in-human Phase 1/2 trial aims to evaluate the safety and efficacy of AAVB-081 using AAVantgarde’s Dual Hybrid platform.

Prof. Simonelli highlighted the potential impact of the study on patient care, while CEO Dr. Natalia Misciattelli emphasized the hope it brings to USH1B patients who currently lack therapeutic options.

About AAVantgarde Bio AAVantgarde Bio develops advanced gene therapy platforms to address large gene delivery challenges, focusing initially on inherited retinal diseases. Co-founded by Professor Alberto Auricchio and the Telethon Foundation, the company aims to meet significant unmet medical needs. For more information, visit www.aavantgarde.com.

If you’d like to help us fund groundbreaking research to defeat Usher syndrome, click the Donate button.